English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCedars-Sinai patient care teams are preparing to offer lecanemab, a new Alzheimer’s disease treatment expected to soon receive approval from the U.S. Food and Drug Administration (FDA), to patients in the coming months.
Tag: Sarah Kremen
What to Know About the Recently Approved Alzheimer’s Drug
The U.S. Food and Drug Administration (FDA) recently granted approval to Lecanemab, the first Alzheimer’s disease treatment to win approval since the largely failed rollout of Aduhelm two years ago.
MEDIA ADVISORY: Cedars-Sinai Experts On Hand to Discuss New Alzheimer’s Drug Now Under Review
The U.S. Food and Drug Administration is poised to make a decision on another new Alzheimer’s disease treatment this week, and experts from the Jona Goldrich Center for Alzheimer’s and Memory Disorders at Cedars-Sinai are available to explain how the drug works and which patients could benefit from the medication.